Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.

advanced gastric cancer --- precision medicine --- new drug development --- gastro-oesophageal cancer --- mutational concordance --- exome sequencing --- formalin fixed paraffin embedded --- biomarkers --- gastric cancer --- metastatic --- body composition --- sarcopenia --- visceral fat area --- subcutaneous fat area --- outcome --- toxicity --- liver metastasis --- conversion surgery --- hepatectomy --- stage iv gastric cancer --- immune checkpoint inhibitors --- Epstein Barr Virus --- tumor mutational burden --- microsatellite instability --- predictive biomarkers --- CAR T cell therapy --- vaccines --- nutritional status --- metastatic gastric cancer --- target therapy --- bone flare --- stage IV --- treatment --- RANK-L --- liquid biopsy --- circulating tumor cell --- cfDNA --- ctDNA --- epithelial–mesenchymal transition --- resistance to treatment --- HER2-inhibition --- VEGFR-inhibition --- immunotherapy --- response monitoring --- n/a --- epithelial-mesenchymal transition

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Gastrointestinal (GI) cancer is a major cause of morbidity and mortality in the world. Since early diagnosis and optimal treatment selection are crucial to improving the prognosis of these diseases, the discovery of useful biomarkers has the potential to greatly reduce their burden. Recent technical and mechanical developments have allowed for the detection of tiny differences in various factors modified in physical conditions, which could contribute to the discovery of novel biomarkers for some diseases.In this Special Issue, we aim to focus on novel biomarkers for GI cancers, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer and biliary cancer. In addition, any samples (tissue, blood, urine and feces) are useful as biomarker sources, although body-fluid-based biomarkers are promising as diagnostic biomarkers due to their noninvasiveness. This Special Issue aims to collect novel insights clarifying the current situation and future perspective in this field.

Medicine --- Oncology --- colorectal cancer --- advanced adenoma --- screening --- stool --- mRNA --- n/a --- cancer screening --- cirrhosis --- AFP --- machine learning --- MALDI-TOF --- proteomics --- CXCR4 --- prognosis --- overall survival --- rectal cancer --- neoadjuvant chemoradiation --- mouse model --- biomarkers --- urokinase plasminogen activator (uPA) --- urokinase plasminogen activator receptor (uPAR) --- plasminogen activator inhibitor type 1 (PAI-1) --- circulating tumour cell (CTC) --- gastric cancer --- oesophageal cancer --- serine proteases --- tumour microenvironment --- serpins --- biomarker --- chemoresistance --- liquid biopsy --- microRNA --- long non-coding RNA --- colorectal neoplasms --- cancer screening tests --- early detection of cancer --- precision medicine --- unfolded protein --- hepatocellular cancer --- GSVA --- unfolded protein score --- epigenetic regulation genes --- somatic mutations --- molecular genetic markers --- extracellular vesicles --- microbiome --- 16S rRNA amplicon --- metagenomics --- liver fibrosis --- hepatocellular carcinoma --- recurrence --- SHG/TPEF microscopy --- artificial intelligence --- advanced gastric cancer --- targeted therapy --- urinary miRNA --- miR-129-1-3p --- miR-566

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Gastrointestinal (GI) cancer is a major cause of morbidity and mortality in the world. Since early diagnosis and optimal treatment selection are crucial to improving the prognosis of these diseases, the discovery of useful biomarkers has the potential to greatly reduce their burden. Recent technical and mechanical developments have allowed for the detection of tiny differences in various factors modified in physical conditions, which could contribute to the discovery of novel biomarkers for some diseases.In this Special Issue, we aim to focus on novel biomarkers for GI cancers, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer and biliary cancer. In addition, any samples (tissue, blood, urine and feces) are useful as biomarker sources, although body-fluid-based biomarkers are promising as diagnostic biomarkers due to their noninvasiveness. This Special Issue aims to collect novel insights clarifying the current situation and future perspective in this field.

Medicine --- Oncology --- colorectal cancer --- advanced adenoma --- screening --- stool --- mRNA --- cancer screening --- cirrhosis --- AFP --- machine learning --- MALDI-TOF --- proteomics --- CXCR4 --- prognosis --- overall survival --- rectal cancer --- neoadjuvant chemoradiation --- mouse model --- biomarkers --- urokinase plasminogen activator (uPA) --- urokinase plasminogen activator receptor (uPAR) --- plasminogen activator inhibitor type 1 (PAI-1) --- circulating tumour cell (CTC) --- gastric cancer --- oesophageal cancer --- serine proteases --- tumour microenvironment --- serpins --- biomarker --- chemoresistance --- liquid biopsy --- microRNA --- long non-coding RNA --- colorectal neoplasms --- cancer screening tests --- early detection of cancer --- precision medicine --- unfolded protein --- hepatocellular cancer --- GSVA --- unfolded protein score --- epigenetic regulation genes --- somatic mutations --- molecular genetic markers --- extracellular vesicles --- microbiome --- 16S rRNA amplicon --- metagenomics --- liver fibrosis --- hepatocellular carcinoma --- recurrence --- SHG/TPEF microscopy --- artificial intelligence --- advanced gastric cancer --- targeted therapy --- urinary miRNA --- miR-129-1-3p --- miR-566